TACAs (Tumor Associated Carbohydrate Antigens) are promising targets for the development of highly specific anti-cancer therapeutics such as monoclonal human antibodies. However, until now the major limiting factor for this advanced therapeutic approach was the availability of purified, chemically defined TACAs in sufficient amounts. Extraction from tumor tissue results in both low quality and low quantity samples. An alternative approach is chemical synthesis, but due to their structural diversity and stereochemical complexity most mammalian glycans are highly challenging targets for every glycochemist. Automated Glycan Assembly (AGA), a technology developed by Prof. Seeberger at the MPICI, enables us to create collections of structurally defined TACAs in a timely manner.